Taselisib Added to Letrozole Boosts Response in Breast Cancer Taselisib Added to Letrozole Boosts Response in Breast Cancer

Taselisib, a PIK3CA targeted agent, in combination with letrozole significantly increased overall response rates in postmenopausal women with ER+/HER2- stage I-III operable breast cancer. ORRs were more robust in patients with PIK3CA mutations.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news